Biota's development program has produced a number of innovative products which have been commercialised and marketed by licensees or partners.
Those products include:
- Zanamivir®; the first in-class neuraminidase inhibitor for the treatment and prophylaxis of influenza, initially launched in 1999 and marketed as Relenza™ by GlaxoSmithKline.
- Inavir® (laninamivir), a second generation long acting neuraminidase inhibitor, has been approved for sale in Japan. Daiichi Sankyo markets Inavir® in Japan.